Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This is the first major study to assess an eight-week regimen in people with all genotypes of hep C and compensated cirrhosis.
This rapid regimen could open the door for more transplantations of HCV-infected organs.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
This hales another victory for improved treatment for hepatitis C.
The indication for AbbVie’s regimen includes those with compensated cirrhosis.
Alert comes after 63 reports of such outcomes, largely in people who should not have received Mavyret, Zepatier or Vosevi.
The presence of less studied HCV genotypes may compromise cure rates.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
Researchers analyzed PPIs’ potential effects on nearly 2,400 participants of nine studies of Mavyret.
The U.S. FDA announced the approval of Mavyret, the first treatment for all hepatitis C genotypes in children ages 12 to 17.
The U.S. FDA approved hepatitis C treatment Mavyret for children from ages 12 to 17 with all genotypes.
The approval applies to those between 12 and 17 years old who have any of the six genotypes of the virus.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
These drugs are approved to treat all six major genotypes of hepatitis C.
This from a real-world analysis of people treated for hep C in the United States.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.